TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

Daily Photo Galleries

Business Photo Galleries

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Camera prevalence approaches sci-fi realm
  2. Experts: If health insurers’ safeguard goes broke, consumers could pay
  3. Paper’s prevalence unlikely to diminish
  4. Rules could kick door open for nuclear power
  5. Nike, Under Armour invest in watching exercisers’ steps
  6. Visa limits vex businesses
  7. Kings Family Restaurants sold to California firm
  8. Scented society is killing cheap perfume industry
  9. Chief of Pittsburgh Regional Alliance sets sights on growth in Southwestern Pennsylvania
  10. Planned Smallman Place condos in Strip District selling fast
  11. Frederick’s seeks bankruptcy after closing lingerie stores